Immunovaccine raises $11.2 million, gets TSX listing

Immunovaccine Inc is moving up from the TSX Venture Exchange to the Toronto Stock Exchange following a successful initial public offering (IPO) and private placement in September. The IPO and private placement raised $9.5 million and $1.7 million respectively for a total of $11.2 million. Immunovaccine will use the proceeds for additional R&D and clinical advancement of its cancer and infectious diseases candidates. The Halifax-based company's lead cancer vaccine is moving into multiple Phase II clinical trials and it is developing potential vaccines for the Ebola virus, anthrax and respiratory syncytial virus....